Literature DB >> 22032287

Underutilization of A2 ABO incompatible kidney transplantation.

Robert R Redfield1, Ronald F Parsons, Eduardo Rodriguez, Moiz Mustafa, James Cassuto, Kumar Vivek, Hooman Noorchashm, Ali Naji, Matthew H Levine, Peter L Abt.   

Abstract

BACKGROUND: ABO compatibility creates a disadvantage for O and B renal allograft candidates. A2 ABO incompatible transplant may decrease waiting times and generate equivalent graft survival to an ABO compatible transplant.
METHODS: Death-censored graft survival was compared between A recipients and O, B, and AB recipients of an A2 allograft with multivariate Cox regression models utilizing data from the United Network of Organ Sharing (UNOS) between 1997 and 2007.
RESULTS: Eighty-five percent of A2 kidneys were transplanted into ABO compatible recipients vs. 15% into ABO incompatible recipients. Rates of A2 incompatible kidney transplants did not increase over the study period (14.8% to 14.6%). Mean wait time for A2→O kidneys was 337 vs. 684 d for O→O and for A2→B kidneys, 542 vs. 734 d for B→B. Adjusted relative risk of graft loss at five-yr was similar between O, B, and AB recipients compared to A recipients of an A2 allograft, corresponding to a five-yr graft survival of 84%, 86.2%, 86.1%, and 86.1%, respectively.
CONCLUSION: A2 incompatible kidney transplantation is underutilized. Graft outcomes are similar among A2 compatible and incompatible recipients. Shorter waiting time and improved access might be achieved if A2 kidneys are considered in all blood groups.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22032287      PMCID: PMC5441562          DOI: 10.1111/j.1399-0012.2011.01543.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  16 in total

1.  Current experience with renal transplantation across the ABO blood group barrier.

Authors:  C F Bryan; P W Nelson; M I Aeder; M L Beck; T S Helling; T M Hughes; A M Luger; G E Pierce; C F Shield
Journal:  Transplant Proc       Date:  1992-12       Impact factor: 1.066

2.  Transplantation of A2 and A2B kidneys from deceased donors into B waiting list candidates increases their transplantation rate.

Authors:  Christopher F Bryan; Paul W Nelson; Charles F Shield; Gilbert Ross; Bradley Warady; Daniel Murillo; Franz T Winklhofer
Journal:  Clin Transpl       Date:  2004

3.  Blood group A and B antigen expression in human kidneys correlated to A1/A2/B, Lewis, and secretor status.

Authors:  Michael E Breimer; Johan Mölne; Gunnela Nordén; Lennart Rydberg; Gilbert Thiel; Christian T Svalander
Journal:  Transplantation       Date:  2006-08-27       Impact factor: 4.939

4.  The effect of race on access and outcome in transplantation.

Authors:  B L Kasiske; J F Neylan; R R Riggio; G M Danovitch; L Kahana; S R Alexander; M G White
Journal:  N Engl J Med       Date:  1991-01-31       Impact factor: 91.245

5.  Long-term survival of kidneys transplanted from live A2 donors to O and B recipients.

Authors:  C F Bryan; P W Nelson; C F Shield; B A Warady; F T Winklhofer; D Murillo; M R Wakefield
Journal:  Am J Transplant       Date:  2007-03-12       Impact factor: 8.086

6.  Transplantation rate of the blood group B waiting list is increased by using A2 and A2B kidneys.

Authors:  C F Bryan; C F Shield; P W Nelson; G E Pierce; G Ross; A M Luger; B A Warady; T S Helling; M I Aeder; J Martinez; T M Hughes; M L Beck; K M Harrell
Journal:  Transplantation       Date:  1998-12-27       Impact factor: 4.939

7.  Increased access to transplantation for blood group B cadaveric waiting list candidates by using A2 kidneys: time for a new national system?

Authors:  Paul W Nelson; Charles F Shield; Nicolas A Muruve; Daniel Murillo; Bradley A Warady; Mark I Aeder; Christopher F Bryan
Journal:  Am J Transplant       Date:  2002-01       Impact factor: 8.086

8.  Successful transplantation of blood group A2 kidneys into non-A recipients.

Authors:  P W Nelson; T S Helling; G E Pierce; G Ross; C F Shield; M L Beck; B Blake; D E Cross
Journal:  Transplantation       Date:  1988-02       Impact factor: 4.939

9.  Current experience with renal transplantation across the ABO barrier.

Authors:  P W Nelson; T S Helling; C F Shield; M Beck; C F Bryan
Journal:  Am J Surg       Date:  1992-11       Impact factor: 2.565

10.  The 'blood group O problem' in kidney transplantation--time to change?

Authors:  Petra Glander; Klemens Budde; Danilo Schmidt; T Florian Fuller; Markus Giessing; Hans-Hellmut Neumayer; Lutz Liefeldt
Journal:  Nephrol Dial Transplant       Date:  2010-01-25       Impact factor: 5.992

View more
  5 in total

1.  Changing organ allocation policy for kidney transplantation in the United States.

Authors:  Bhavna Chopra; Kalathil K Sureshkumar
Journal:  World J Transplant       Date:  2015-06-24

2.  Race/ethnicity is associated with ABO-nonidentical liver transplantation in the United States.

Authors:  Jin Ge; John P Roberts; Jennifer C Lai
Journal:  Clin Transplant       Date:  2017-06-19       Impact factor: 2.863

Review 3.  Strategies to overcome the ABO barrier in kidney transplantation.

Authors:  Georg A Böhmig; Andreas M Farkas; Farsad Eskandary; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2015-09-01       Impact factor: 28.314

4.  Economic Impacts of ABO-Incompatible Live Donor Kidney Transplantation: A National Study of Medicare-Insured Recipients.

Authors:  D Axelrod; D L Segev; H Xiao; M A Schnitzler; D C Brennan; V R Dharnidharka; B J Orandi; A S Naik; H Randall; J E Tuttle-Newhall; K L Lentine
Journal:  Am J Transplant       Date:  2016-02-08       Impact factor: 8.086

Review 5.  Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients.

Authors:  Krista L Lentine; David Axelrod; Christina Klein; Christopher Simpkins; Huiling Xiao; Mark A Schnitzler; Janet E Tuttle-Newhall; Vikas R Dharnidharka; Daniel C Brennan; Dorry L Segev
Journal:  Transplantation       Date:  2014-07-15       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.